Walgreens Opioid Whistleblower Ruling: Judge Sends Novak to State Courts Over $4.7 Billion Deal

The Walgreens opioid whistleblower ruling is a jurisdictional loss, not a merits loss: on Tuesday, September 29, 2026, U.S. District Judge Joan H. Lefkow in Chicago declined to decide pharmacist T.J. Novak's claim to a share of Walgreens Boots Alliance's roughly $4.7 billion 2022 settlement with the states, and terminated his case. She held that a federal court cannot order individual states to carve whistleblower money out of their opioid settlements, and that Novak's theory depends on unresolved law in 28 states whose own courts should decide it.

That leaves the most interesting question in the case unanswered. Novak, who already collected a share of more than $25 million from the federal government's 2025 False Claims Act settlement with Walgreens, contends that the states' separate deal wiped out the whistleblower claims he pled under their False Claims Acts, and that he should be paid from it. The states say opioid settlement money is earmarked for treatment and abatement, not relator awards. After the Walgreens opioid whistleblower ruling, that fight moves, if it moves at all, to state courthouses.

What did the judge decide about the Walgreens opioid whistleblower?

Judge Lefkow ruled that Novak had not shown why the Northern District of Illinois should exercise supplemental jurisdiction over his state-law claims to part of the multistate settlement, and she declined to do so. Three points from the order, as reported by Reuters, Bloomberg Law and Law360, carry the decision:

• No federal power over the states' money. The court said it lacked authority to require individual states to set aside part of their settlements with Walgreens for Novak.
• Twenty-eight bodies of unsettled law. Novak's entitlement, if any, depends on how 28 different state False Claims Acts treat a relator when the state resolves the underlying conduct through some other route. The judge said those states' courts should decide those questions.
• Case terminated. The order ended the federal action, which had been open since 2018.

The ruling is not a finding that Novak has no right to anything. It is a decision about forum. That distinction matters for relators' counsel and for the state attorneys general who negotiated the 2022 deal, because the substantive question, whether a state's opioid settlement is an "alternate remedy" that triggers a relator share, remains open in every one of those states.

Who is T.J. Novak, and how much did he get from the federal settlement?

T.J. Novak is a pharmacist, registered in Illinois since 1982, who worked as a Walgreens pharmacist and filed a sealed qui tam complaint in the Northern District of Illinois on August 10, 2018. His suit alleged that Walgreens filled invalid prescriptions for opioids and other controlled substances and then billed Medicare, Medicaid and other federal health programs for them. Three more qui tam suits with substantially similar allegations followed, and the cases were consolidated under Novak's lead docket, No. 18 C 5452, alongside Nos. 22 C 6052, 22 C 6366 and 23 C 1617.

The Justice Department intervened and filed its own complaint on January 16, 2025, alleging that from about August 2012 to March 2023 Walgreens pharmacists filled millions of controlled-substance prescriptions despite clear red flags, such as excessive quantities, early refills and the opioid-benzodiazepine-muscle relaxant combination known as the "trinity," and that the company pressured pharmacists to fill quickly rather than verify. On April 21, 2025, Walgreens settled for $300 million, plus another $50 million if the company was sold, merged or transferred before fiscal year 2032. Walgreens denied wrongdoing.

The four relators, Novak, Elmer Mosley, Ph.D., K&V Group, LLP and Patrick Awa, shared 17.25% of the federal False Claims Act recovery, more than $25 million. That percentage sits inside the 15% to 25% range the federal statute, 31 U.S.C. § 3730(d)(1), sets when the government intervenes.

Date	Event
Aug. 10, 2018	Novak files qui tam suit under seal in the Northern District of Illinois (No. 18 C 5452)
Dec. 12, 2022	Attorneys general announce CVS and Walgreens opioid settlements; Walgreens' share is roughly $4.7 to $4.8 billion to states and subdivisions
2022–2023	Three further qui tam suits filed (Nos. 22 C 6052, 22 C 6366, 23 C 1617) and later consolidated
Jan. 16, 2025	Justice Department files its complaint against Walgreens in Chicago
Apr. 21, 2025	Federal settlement: $300 million, plus $50 million contingent on a sale before FY2032; relators share 17.25% (over $25 million)
Aug. 28, 2025	Sycamore Partners completes its acquisition of Walgreens Boots Alliance
After 2025	Novak presses claim to part of the states' settlement; North Carolina, Virginia and other states oppose
Sept. 29, 2026	Judge Lefkow declines supplemental jurisdiction and terminates the case

The Sycamore closing is relevant only as background: the federal agreement made an additional $50 million payable on a pre-2032 sale, and the sale closed in August 2025. Whether and when that payment was made, and how it was split, is not in the public reporting on the September 29 order.

How much is the Walgreens multistate opioid settlement?

Reports describe the same deal as $4.7 billion (Reuters, Law360) or roughly $4.8 billion (Bloomberg Law), and the national settlement administrator's figure for Walgreens is up to $5.52 billion over 15 years. The numbers measure different things.

Figure	What it covers	Source
~$4.7 billion	The states' settlement as described in coverage of Novak's challenge	Reuters; Law360
~$4.8 billion	Walgreens' framework figure for remediation payments to settling states and subdivisions, over 15 years	Bloomberg Law; Walgreens filings
~$155 million	Walgreens' separate framework for tribal claims	Walgreens filings
Up to $5.52 billion	All-in figure including prior state settlements, attorneys' fees and costs, over 15 years	National Opioid Settlement executive summary
$300 million + $50 million contingent	The separate 2025 federal False Claims Act settlement; not part of the state deal	Justice Department

The 2022 deal was a nationwide Global Settlement negotiated by a bipartisan coalition of attorneys general and announced on December 12, 2022 alongside a parallel CVS agreement, together worth more than $10 billion. It resolved state and local government claims, including many of the subdivision cases consolidated in the opioid Multidistrict Litigation (MDL) in the Northern District of Ohio. Like the earlier distributor and manufacturer deals, it directs most of the money to opioid remediation programs over a long payout schedule. Novak's federal recovery came from a different pot: the 2025 Justice Department settlement over federal health care program billing.

Why can't the Walgreens whistleblower get a share of the state settlement in federal court?

Because the only hook for a federal court was supplemental jurisdiction, and Judge Lefkow chose not to use it. Novak's claim to the states' money arises under state law, so it could be heard in federal court only as a claim related to his federal False Claims Act case under 28 U.S.C. § 1367. Section 1367(c) lets a district court decline that jurisdiction when, among other grounds, a claim "raises a novel or complex issue of State law," when the state claim substantially predominates, when the federal claims have been dismissed, or in exceptional circumstances.

Each of those grounds fit. The federal claims had been resolved by the 2025 settlement. What remained was a dispute between a private relator and 28 sovereign states over how their own statutes allocate their own settlement money, with no controlling appellate decisions in most of them. A federal judge asked to answer that question 28 times, with each answer binding only until a state appellate court said otherwise, has strong reasons to decline.

The court's other observation, that it lacked authority to order the states to set money aside, adds a second layer. Even if the court had kept the claims, a federal order directing state treasuries to reserve settlement funds would raise sovereign immunity and comity problems, which a decision to decline jurisdiction avoids altogether.

Can a whistleblower get a share of a state settlement under a state False Claims Act?

Sometimes, and that is precisely the open question Novak will now have to litigate state by state. The federal statute contains an "alternate remedy" clause, 31 U.S.C. § 3730(c)(5): the government may pursue its claim "through any alternate remedy available," and if it does, the relator keeps "the same rights in such proceeding" as if the qui tam action had continued, including the right to a share. Many state False Claims Acts copy that language or a version of it.

Novak's argument, as Reuters described it, is that the states' 2022 deal resolved the same Walgreens dispensing conduct his complaint alleged under state False Claims Acts, and in doing so improperly ended those state claims. If the deal was an alternate remedy for the conduct in his complaint, the argument runs, he is entitled to a relator's percentage of it.

The states' answer has two parts. First, the multistate opioid deals were negotiated as public nuisance, consumer protection and abatement settlements, not as False Claims Act recoveries for false billing, so they are not an alternate remedy for the claims he filed. Second, the money is committed to opioid treatment, prevention and recovery under the settlement terms, which in their view leaves no room for whistleblower payouts. North Carolina and Virginia were among the states pressing that position.

Neither side's position is obviously right across all 28 states, because state statutes differ on whether they include an alternate-remedy clause at all, whether it covers settlements as well as administrative proceedings, and how a relator share is calculated when the state's recovery rests on different legal theories. That variation is exactly what made the case a poor fit for a single federal judge.

What happens next in the Walgreens whistleblower case?

Novak's options are to refile in state court, to appeal the jurisdictional ruling to the Seventh Circuit, or to stop. A district court's decision to decline supplemental jurisdiction is reviewed for abuse of discretion, a deferential standard, which makes state court the more likely path for anyone seeking to keep the claims alive. No appeal or state filing had been reported as of October 2, 2026.

Timing is governed by 28 U.S.C. § 1367(d). The Statute of Limitations for a state claim dismissed under § 1367(c) "shall be tolled while the claim is pending and for a period of 30 days after it is dismissed unless State law provides for a longer tolling period." In Artis v. District of Columbia, 583 U.S. 71 (2018), the Supreme Court read that as a stop-the-clock rule: the limitations period is suspended while the claim is in federal court and resumes running 30 days after dismissal. Any state-court filings would have to be measured, state by state, against whatever time remained on each state's clock, together with any savings statute the state offers.

The practical burden is heavy. Pursuing up to 28 separate actions against states that negotiated the deal, each raising its own question of first impression and each potentially facing sovereign immunity defenses, is a costly undertaking for an individual relator who has already been paid on the federal side.

Does the ruling affect opioid settlement money going to states and localities?

No. The order leaves the 2022 Walgreens settlement and its payment schedule untouched, and nothing in it requires any state to reserve funds for Novak. Counties, cities and opioid abatement boards receiving Walgreens installments continue to receive them on the existing schedule.

The longer-term risk for states is narrower: if a state court later holds that its False Claims Act's alternate-remedy clause reaches an opioid settlement, that state could face a relator-share claim against its portion. The ruling defers that risk; it does not eliminate it.

What it means for relators, attorneys general, mass tort firms and defendants

For qui tam relators and their counsel. A relator who pleads state False Claims Act counts alongside federal ones should assume that, once the federal claims settle, a federal court will not adjudicate a claim against the states' separate recoveries. The cleaner path is to negotiate relator-share terms with each state before it settles, or to file in state court early, rather than relying on supplemental jurisdiction after the fact. Contingency Fee arrangements with relators should reflect the cost of multistate follow-on litigation.

For state attorneys general. Multistate settlements that resolve conduct also alleged in a pending, sealed qui tam case carry latent alternate-remedy exposure. Express release and allocation language addressing relator claims, and coordination with relators before signing, reduce the chance of a later carve-out demand.

For mass tort and personal injury firms. Public-entity opioid work has run alongside qui tam litigation for years, often over the same dispensing conduct. Firms representing counties and abatement recipients can treat this ruling as confirming that federal courts will not reach into settlement distributions on a relator's behalf, while noting that state courts remain free to read their statutes differently.

For corporate defendants. Walgreens itself is not paying anything new because of this dispute, which is between Novak and the states. The episode still shows why settlement agreements with the federal government, the states and private relators should be sequenced and drafted together where overlapping conduct is in play.

FAQ

What did the court decide in the Walgreens whistleblower case?

On September 29, 2026, Judge Joan Lefkow of the Northern District of Illinois declined to hear T.J. Novak's claim to a share of Walgreens' roughly $4.7 billion multistate opioid settlement and terminated the case, saying the claims depend on unsettled law in 28 states whose courts should decide them.

How much did T.J. Novak receive from Walgreens?

Novak and three other relators shared 17.25% of the federal False Claims Act recovery from Walgreens' April 2025 settlement of $300 million plus a $50 million contingent payment, which Reuters reports came to more than $25 million.

Did Novak lose on the merits?

No. The court ruled on jurisdiction, not on whether a state's opioid settlement triggers a relator share. Novak may still pursue those claims in state courts, subject to each state's limitations period as tolled by 28 U.S.C. § 1367(d).

Why do the states oppose paying the whistleblower?

States including North Carolina and Virginia argue the settlement money is dedicated to opioid treatment and abatement, not whistleblower compensation, and that the 2022 deal was not a substitute for Novak's False Claims Act case.

Is the Walgreens multistate opioid settlement affected?

No. The ruling leaves the settlement and its payment schedule to states and localities in place and does not require any state to set funds aside.

Is this related to the opioid MDL?

Indirectly. The 2022 Walgreens deal resolved many state and local government claims, including subdivision cases in the national opioid MDL in Ohio, but Novak's case was a separate qui tam action in Chicago and was never part of the MDL.